All News

RheumNow Podcast square

An Epidural Letdown (4.4.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
hip.THR_.jpg

Joint Implant Metals May Be Leaking

MedPage Today

Patients with metal-containing joint replacements had significantly higher concentrations of cobalt in their cerebrospinal fluid (CSF) relative to patients without arthroplasties, researchers reported.

Read Article
RheumNow Podcast square

Cancer Survival with TNF Inhibitors (3.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
HLA-B%2A2705.png

Worse Outcomes in HLA-B27+ JIA

MedPage Today

Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study.

Read Article
morbidity,covid,heart,lung,brain

Predicting Premature Death with Multimorbidity

Jack Cush, MD

Machine learning (ML) models were used to predict premature death in inflammatory bowel disease (IBD) patients with multimorbidity, the co-occurrence of 2 or more chronic conditions. 

Read Article
JAK Janus

Treating chronic inflammatory diseases with JAK inhibitors

Science Daily

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Read Article
Medical.costs.RMD

Autoimmune Disease Impact Report

Jack Cush, MD

Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: rheumatoid arthritis, multiple sclerosis, inflammat

Read Article
A study in Alberta, Canada, examining the travel burdens for rheumatoid arthritis patients, found a median travel time of 13 minutes to reach general practitioners and 34 minutes to see rheumatologists. The research highlighted significant disparities between rural and urban https://t.co/2kYDrk16O8
Dr. John Cush RheumNow ( View Tweet)
Obstacles to the current use of DMARDs from patients, discussed during regular appointments, were mainly associated with adverse effects and worries about effectiveness and long-term usage. Ongoing attention to these patients' concerns is crucial for improving treatment https://t.co/hWYGiPIsBb
Dr. John Cush RheumNow ( View Tweet)
Barriers to current DMARD use from pts, discussed during routine visits were primarily related to side effects and concerns about the efficacy and long-term use. Continuous attention to these patients’ concerns are key to better treatment adherence https://t.co/J0kPR2CQyH https://t.co/D84t4dPdLO

Links:

Dr. John Cush RheumNow ( View Tweet)
Targeting Obesity in Rheumatic Disease Patients Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese. https://t.co/OYtsbfJQ2e https://t.co/xEZI3mkY0q

Links:

Dr. John Cush RheumNow ( View Tweet)
Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/MaWx6AZ0JF
Dr. John Cush RheumNow ( View Tweet)
In 2021 the global rheumatoid arthritis market was valued at USD 22.77 billion and is expected to reach USD 33.30 billion by 2030. https://t.co/0vU6QP9JiG https://t.co/a8jXwk3KbK

Links:

Dr. John Cush RheumNow ( View Tweet)
MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/8zJ0OBWjbm
Dr. John Cush RheumNow ( View Tweet)
Researchers have developed a machine learning model capable of predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis. In the KURAMA cohort of 210 SN patients, 57 (27%) progressed to RA. The FNN model excelled with an AUC of 0.924 and 81% https://t.co/b8G2AzMZ7m
Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk

Links:

Dr. John Cush RheumNow ( View Tweet)
ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting non-glycine citrulline motifs assoc. more strongly w/ HLA-SE; ACPA to glycine citrulline motifs assoc. w/ smoking and IgA ACPA A&R https://t.co/PmKv3dZLc4 https://t.co/NdPG4Orfj4

Links:

ACR_Journals ACR_Journals ( View Tweet)
Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/3k6ZJTybAb
Dr. John Cush RheumNow ( View Tweet)
Veterans Admin (VA) EHR study of #RA-associated ILD (n 1047), matched 237 RA-ILD pts who Rx w/ TNFi vs 237 Rx w/ non-TNF biologics (mean age 68y; 92% male). Death & Resp hospitalisation were similar (adj HR 1·21, 1·27), as was mortality (1·15), Resp mortality (1·38) https://t.co/03LV5B4FSV
Dr. John Cush RheumNow ( View Tweet)
617 seropos ARTHRALGIA pts - 34% got inflamm. arthritis (avg time ~20mos). Arthritis risk factors: high ACPA (HR 4.7) or double positive(HR 6.8); 1st degree relative (1.5); intermittent Sxs(1.6); <12 mos Sxs (HR 0.71); AM stiff ≥1hr (1.6); joint swelling (1.5). IF > 2 https://t.co/tHL19ro5C8
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×